Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826221 | 0.95 | MKNK1 (0.42) | TLR7TLR8MKNK1MKNK2ATR | |
| SCHEMBL826126 | 0.93 | TLR7 (0.47) | TLR7TLR8MKNK1MKNK2ATR | |
| SCHEMBL826144 | 0.89 | TLR7 (0.43) | TLR7TLR8MKNK1MKNK2MAP4K4 | |
| SCHEMBL823695 | 0.89 | TLR7 (0.48) | TLR7TLR8MKNK1MKNK2ATR | |
| SCHEMBL826445 | 0.87 | MKNK1 (0.45) | MKNK1MKNK2ATRMAP4K4TTK | |
| SCHEMBL825916 | 0.86 | MKNK1 (0.42) | TLR7TLR8MKNK1MKNK2ATR | |
| SCHEMBL825946 | 0.86 | MKNK1 (0.44) | MKNK1MKNK2ATRMAP4K4TTK | |
| SCHEMBL826135 | 0.86 | MKNK1 (0.42) | TLR7TLR8MKNK1MKNK2ATR | |
| SCHEMBL825839 | 0.85 | MKNK1 (0.44) | MKNK1MKNK2ATRMAP4K4TTK | |
| SCHEMBL823774 | 0.84 | MKNK1 (0.43) | TLR7TLR8MKNK1MKNK2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | claimed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008077649-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | TLR7 1598/4885TLR8 2236/4885MKNK1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.